FOR THE TREATMENT OF ALL TYPES OF OVARIAN CANCER, EITHER SUPPLEMENTARY TO SURGERY OR PALLIATIVELY. BECAUSE OF LACK OF CROSS-RESISTANCE REPORTED BETWEEN TREOSULFAN AND OTHER CYTOTOXIC AGENTS TREOSULFAN MAY BE USEFUL IN ANY NEOPLASM REFRACTIVE TO CONVENTIONAL THERAPY.
TREOSULFAN HAS BEEN USED IN COMBINATION REGIMENS IN CONJUNCTION WITH VINCRISTINE, METHOTREXATE, 5-FU AND PROCARBAZINE.
TREOSULFAN 1 G DAILY IS LICENSED FOR USE BY MOUTH IN 4 DIVIDED DOSES FOR 2 OR 4 WEEKS FOLLOWED BY THE SAME PERIOD WITHOUT TREATMENT. ALTERNATIVELY 1.5 G DAILY IN 3 DIVIDED DOSES MAY BE GIVEN FOR 1 WEEK, FOLLOWED BY 3 WEEKS WITHOUT THERAPY. THE CYCLE IS THEN REPEATED, THE DOSE BEING ADJUSTED IF NECESSARY ACCORDING TO THE EFFECT ON BONE MARROW. DOSES OF 3 TO 8 G/M2 MAY INSTEAD BE GIVEN INTRAVENOUSLY EVERY 1 TO 3 WEEKS. DOSES LARGER THAN 3 G/M2 SHOULD BE GIVEN BY INFUSION AT A RATE OF 3 G/M2 EVERY 5 TO 10 MINUTES. DOSES UP TO 1.5 G/M2 HAVE BEEN GIVEN INTRAPERITONEALLY. LOWER DOSES SHOULD BE USED IF TREATMENT WITH OTHER ANTINEOPLASTIC DRUGS OR RADIOTHERAPY IS BEING GIVEN.